Skip to main content

Vytorin Side Effects

Generic name: ezetimibe / simvastatin

Medically reviewed by Drugs.com. Last updated on Feb 21, 2023.

Note: This document contains side effect information about ezetimibe / simvastatin. Some dosage forms listed on this page may not apply to the brand name Vytorin.

Applies to ezetimibe / simvastatin: oral tablet.

Serious side effects of Vytorin

Along with its needed effects, ezetimibe / simvastatin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ezetimibe / simvastatin:

Incidence not known

Other side effects of Vytorin

Some side effects of ezetimibe / simvastatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to ezetimibe / simvastatin: oral tablet.

General

The more commonly reported adverse effects have included headache, increased ALT, myalgia, upper respiratory tract infection, and diarrhea.

Gastrointestinal

Ezetimibe-simvastatin:

Common (1% to 10%): Diarrhea

Ezetimibe:

Common (1% to 10%): Diarrhea, abdominal pain, nausea

Postmarketing reports: Pancreatitis

Simvastatin:

Common (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, pancreatitis, anorexia, vomiting, gastritis

Very rare (less than 0.01%): Protein losing enteropathy[Ref]

Musculoskeletal

Simvastatin has been associated with rare cases of severe myopathy and rhabdomyolysis. This is accompanied by elevations in creatine kinase, myoglobinuria, and proteinuria, as well as renal failure. Experience with HMG-CoA reductase inhibitors indicates that concomitant use with gemfibrozil, niacin, cyclosporine, or erythromycin may increase the incidence and the severity of musculoskeletal side effects.

A case of spontaneous biceps tendon rupture developed in a patient after 4 months of treatment with ezetimibe-simvastatin. Upon rechallenge 2 months later, the patient developed pain in the contralateral arm overlying the biceps tendon. Following discontinuation of ezetimibe-simvastatin, pain resolved 2 weeks later. Inhibition of matrix metalloproteinases has been suggested as the contributing factor in the development of tendon rupture.[Ref]

Ezetimibe-simvastatin:

Common (1% to 10%): Myalgia, extremity pain

Very rare (less than 0.01%): Tendon rupture (one case)

Frequency not reported: Back pain

Postmarketing reports: Muscle cramps

Ezetimibe:

Common (1% to 10%): Back pain, arthralgia

Postmarketing reports: Myalgia, elevated creatine phosphokinase, rare reports of myopathy/rhabdomyolysis

Simvastatin:

Uncommon (0.1% to 1%): Myopathy, rhabdomyolysis

Frequency not reported: Elevations in creatine kinase, dermatomyositis, arthralgia, myalgia[Ref]

Renal

Simvastatin:

Frequency not reported: Myoglobinuria, acute renal failure secondary to rhabdomyolysis[Ref]

Hepatic

Persistent elevations in liver function tests three times normal values are reported in up to 1.5% of patients on simvastatin in clinical trials. In one study, this led to the discontinuation of simvastatin in 0.6% of patients. In other patients, elevations in liver function tests were transient and returned to normal with continued simvastatin therapy.[Ref]

Ezetimibe-simvastatin:

Common (1% to 10%): Increased ALT

Frequency not reported: Increased AST

Ezetimibe:

Postmarketing reports: Elevations in liver transaminases, hepatitis, cholelithiasis, cholecystitis

Simvastatin:

Common (1% to 10%): Elevations in liver function tests

Frequency not reported: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, fulminant hepatic necrosis

Postmarketing reports: Hepatic failure, jaundice[Ref]

Dermatologic

Simvastatin:

Frequency not reported: Eczematous, pruritic rash, toxic epidermal necrolysis, photosensitivity, purpura, erythema multiforme, photosensitivity, purpura, alopecia

Postmarketing reports: A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)[Ref]

Immunologic

Ezetimibe-simvastatin:

Frequency not reported: Influenza

Ezetimibe:

Common (1% to 10%): Viral infection

Simvastatin:

Very rare (less than 0.01%): Lupus-like syndrome

Frequency not reported: Positive ANA, ESR increase, polymyalgia rheumatica, vasculitis

Statin use:

Rare (0.01% to 0.1%): Immune-mediated necrotizing myopathy (IMNM)[Ref]

Respiratory

Ezetimibe-simvastatin:

Common (1% to 10%): Upper respiratory tract infection

Frequency not reported: Interstitial lung disease causing breathing problems including persistent cough and/or shortness of breath or fever

Ezetimibe:

Common (1% to 10%): Coughing

Frequency not reported: Sinusitis

Simvastatin:

Frequency not reported: Sinusitis, pharyngitis[Ref]

Cardiovascular

Simvastatin:

Common (1% to 10%): Angina

Frequency not reported: Atrial fibrillation, edema[Ref]

Endocrine

Simvastatin:

Frequency not reported: Gynecomastia, thyroid function abnormalities[Ref]

Genitourinary

Simvastatin:

Frequency not reported: Erectile dysfunction, impotence, urinary tract infections[Ref]

Hematologic

A 65-year-old male with hereditary hemorrhagic telangiectasia (HHT) who had a history of minimal epistaxis began to experience profuse epistaxis 8 to 10 weeks after starting ezetimibe-simvastatin, The patient had been treated with simvastatin 20 mg alone for 9 years without any adverse effects. Two months after starting combination therapy with ezetimibe-simvastatin he noticed epistaxis that increased from a few drops every other day to profuse bleeding for 20 to 30 minutes daily. The patient reported initiation of ezetimibe-simvastatin as the only change in his treatment regimen in the past year. When he stopped ezetimibe-simvastatin, his epistaxis decreased. After six weeks without ezetimibe-simvastatin, he had only one moderate nose bleed. Four months later, the patient's hemoglobin was stable. He then started simvastatin 40 mg monotherapy. The profound epistaxis returned and the patient discontinued the medication. It remains unclear whether the patient's accelerated epistaxis was due to the combination therapy or the double dosage of simvastatin.[Ref]

Ezetimibe-simvastatin:

Postmarketing reports: Epistaxis (one report), anemia

Ezetimibe:

Postmarketing reports: Thrombocytopenia

Simvastatin:

Frequency not reported: Hemolytic anemia, thrombocytopenia, leukopenia (possibly manifestations of a hypersensitivity reaction)[Ref]

Hypersensitivity

Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported. In addition, an apparent hypersensitivity syndrome has been reported rarely that has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.[Ref]

Ezetimibe:

Postmarketing reports: Angioedema, anaphylaxis, rash, urticaria

Simvastatin:

Rare (less than 0.1%): Erythema multiforme, Stevens-Johnson syndrome, anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea

Postmarketing reports: Hypersensitivity reactions[Ref]

Nervous system

A case of memory loss possibly related to simvastatin use has been reported. The patient developed gradual memory loss following 12 months of simvastatin therapy. He was switched to pravastatin, and within a month his memory was intact. Rechallenge with simvastatin was not performed.

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These reports have been generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).[Ref]

Ezetimibe-simvastatin:

Common (1% to 10%): Headache

Frequency not reported: Confusion, fatigue

Ezetimibe:

Postmarketing reports: Dizziness, paraesthesia

Simvastatin:

Frequency not reported: Cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy

Statins:

Postmarketing reports: Cognitive impairment[Ref]

Ocular

Simvastatin:

Frequency not reported: Progression of cataracts, ophthalmoplegia[Ref]

Oncologic

Simvastatin:

Frequency not reported: Liver, thyroid, and lung adenomas and carcinomas[Ref]

Psychiatric

Simvastatin:

Frequency not reported: Depression, suicidal thoughts, delusions, paranoia, agitation, decreased libido, anxiety, insomnia[Ref]

Metabolic

Simvastatin:

Frequency not reported: Increases in HbA1c and fasting serum glucose levels

Other

Ezetimibe:

Frequency not reported: Fatigue, asthenia[Ref]

References

1. Walker JF. Simvastatin: the clinical profile. Am J Med. 1989;87:s44-6.

2. Simons LA. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators. Clin Cardiol. 1993;16:317-22.

3. Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol. 1985;19:51-7.

4. Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol. 1992;87:257.

5. Product Information. Zocor (simvastatin). Merck & Co., Inc. 2001;PROD.

6. Plosker GL, Mctavish D. Simvastatin - a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995;50:334-63.

7. Product Information. Zetia (ezetimibe). Schering-Plough Corporation. 2002.

8. Product Information. Vytorin (ezetimibe-simvastatin). Merck & Co., Inc. 2004.

9. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109-10.

10. McDonagh J, Winocour P, Walker DJ. Musculoskeletal manifestations during simvastatin therapy. Br J Rheumatol. 1993;32:647-8.

11. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study. Arch Intern Med. 1996;156:2085-92.

12. Yurdakok M, Gurakan B, Ergin H, Kirazli S. Plasma concentrations of granulocyte colony stimulating factor in preterm infants in the first few hours of life. Acta Paediatr. 1996;85:1389-90.

13. Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-4.

14. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-4.

15. Alvarez JM, Rawdanowiz TJ, Goldstein J. Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg. 1998;116:654-5.

16. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med. 2000;108:351-2.

17. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-10.

18. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol. 1994;33:199.

19. ChoquetKastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A. Eosinophilic fasciitis and simvastatin. Arch Intern Med. 2001;161:1456-7.

20. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 2001;86:4556-9.

21. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001;15:1747-8.

22. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron. 2001;89:117-8.

23. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J. 2001;94:1023-6.

24. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-95.

25. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother. 2002;36:820-3.

26. Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels. Ann Intern Med. 2002;137:I45.

27. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137:617-8.

28. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40:163-71.

29. Itakura H, Vaughn D, Haller DG, O'Dwyer PJ. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol. 2003;169:613.

30. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe / simvastatin (vytorin). Am J Cardiol. 2006;97:223-8.

31. Havranek JM, Wolfsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy. Am J Med. 2006;119:285-6.

32. Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, Thompson PD. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 2007;100:152-3.

33. Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP. 1991;25:257-64.

34. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999;353:1763-4.

35. Feldmann R, Mainetti C, Saurat JH. Skin lesions due to treatment with simvastatin (Zocor). Dermatology. 1993;186:272.

36. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186:248-52.

37. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin. Arch Intern Med. 1992;152:1093.

38. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors - Report of 4 cases and review of the literature. Medicine. 1998;77:378-83.

39. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

40. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother. 1996;30:192.

41. Katznelson S. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int. 1999;56:s117-21.

42. Shah B, McAllister A, Davidson TM. Increased epistaxis with use of ezetimibe / simvastatin. Ann Pharmacother. 2009;43:1545.

43. Phan T, Mcleod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995;58:625-8.

44. Orsi A, Sherman O, Woldeselassie. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-9.

45. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58:1333-7.

46. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55-60.

47. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716-23.

48. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet. 1993;341:114.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.